52116-39-9

Upstream product

• 5446-02-6 4-methoxymethylsalicylate 
• 105-36-2 ethyl bromoacetate 
• 673-22-3 2-Hydroxy-4-methoxybenzaldehyde 
• 79-11-8 chloroacetic acid 
• 60102-29-6 (3R)-2'-hydroxy-4',7-dimethoxyisoflavan 
• 7732-18-5 water 
• 53295-41-3 3,9,10-trimethoxy-7,11b-dihydro-indeno[2,1-c]chromen-6a-ol 
• 857551-85-0 3,6A,9,10-tetramethoxy-6a,7-dihydro-6H-indeno[2,1-c]chromen-11b-ol 
• 64-19-7 acetic acid 
• 33562-12-8 methyl 4-methoxy-2-(2-methoxy-2-oxoethoxy)benzoate 
• 860696-37-3 2-ethoxycarbonylmethoxy-4-methoxy-benzoic acid ethyl ester 
• 796851-72-4 methyl 2-(2-ethoxy-2-oxoethoxy)-4-methoxybenzoate 
• 7664-93-9 sulfuric acid 

Downstream Products

• 2088-24-6 3-methoxyphenoxyacetic acid 
• 15832-09-4 6-methoxy-3-coumaranone 
• 33562-12-8 methyl 4-methoxy-2-(2-methoxy-2-oxoethoxy)benzoate 

Relevant academic research and scientific papers

Total synthesis of (?)-4-desacetoxy-1-oxovindoline: Single atom exchange of an embedded core heteroatom in vindoline

A concise total synthesis of (?)-4-desacetoxy-1-oxovindoline is disclosed, bearing a single heteroatom exchange in the core structure of the natural product 4-desacetoxyvindoline. Central to the synthesis is powerful oxadiazole intramolecular [4 + 2]/[3 +

Novel benzofuran derivatives with dual 5-HT1A receptor and serotonin transporter affinity

Several benzofuran derivatives linked to a 3-indoletetrahydropyridine through an alkyl chain were prepared and evaluated for serotonin transporter and 5-HT1A receptor affinities. Their design, synthesis and structure-activity relationships are described.

BENZOFURANYL- AND BENZOTHIENYL- PIPERAZINYL QUINOLINES AND METHODS OF THEIR USE

Benzofuranyl- and benzothienyl-piperzinyl quinoline derivatives and compositions containing such compounds are disclosed. Methods of using benzofuranyl- and benzothienyl-piperzinyl quinoline derivatives and compositions containing such composition in the treatment and/or prevention of serotonin-related disorders, such as depression and anxiety, are also disclosed. In addition, processes for the preparation of benzofuranyl- and benzothienyl-piperzinyl quinoline derivatives are disclosed.

Synthesis, antibacterial activity, and quantitative structure-activity relationships of new (Z)-2-(nitroimidazolylmethylene)-3(2 H)-benzofuranone derivatives

A new series of (Z)-2-(1-methyl-5-nitroimidazole-2-ylmethylene)-3(2 H)-benzofuranones (11a-p) and (Z)-2-(1-methyl-4-nitroimidazole-5-ylmethylene)-3(2 H)-benzofuranones (12a-m) were synthesized and assayed for their antibacterial activity against Gram-positive and Gram-negative bacteria. Most of the 5-nitroimidazole analogues (11a-p) showed a remarkable inhibition of a wide spectrum of Gram-positive bacteria (Staphylococcus aureus, Streptococcus epidermidis, MRSA, and Bacillus subtilis) and Gram-negative Klebsiella pneumoniae, whereas 4-nitroimidazole analogues (12a-m) were not effective against selected bacteria. The quantitative structure-activity relationship investigations were applied to find out the correlation between the experimentally evaluated activities with various parameters of the compounds studied. The QSAR models built in this work had reasonable predictive power and could be explained by the observed trends in activities.

BENZOFURANYL-AND BENZOTHIENYL-PIPERAZINYL QUINOLINES AND METHODS OF THEIR USE

Benzofuranyl-and benzothienyl-piperzinyl quinoline derivatives and compositions containing such compounds are disclosed. Methods of using benzofuranyl- and benzothienyl-piperzinyl quinoline derivatives and compositions containing such composition in the treatment and/or prevention of serotonin-related disorders, such as depression and anxiety, are also disclosed. In addition, processes for the preparation of benzofuranyl- and benzothienyl-piperzinyl quinoline derivatives are disclosed.